Precision drug olaparib may be effective without hormone therapy for some men with biochemically recurrent prostate cancer

Estimated reading time: 1 minutes

• About The Author

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to results of a phase II clinical trial of 51 patients.

About The Author

See author's posts

Trending

Why Young Athletes Should Care About Joint Health Early On